Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997284 | 1.00 | MMP1 (0.35) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL3355253 | 0.81 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3355257 | 0.81 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4798136 | 0.79 | SLC1A3 (0.45) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL2987274 | 0.79 | SLC1A3 (0.45) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL2987273 | 0.79 | SLC1A3 (0.45) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL25832508 | 0.79 | MMP2 (0.36) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL4778798 | 0.78 | TSHR (0.36) | MMP1MMP2MMP3MMP7TSHR | |
| SCHEMBL8422179 | 0.77 | TSHR (0.39) | MMP1MMP2MMP3MMP7GRIK1 | |
| SCHEMBL3355256 | 0.77 | TSHR (0.39) | MMP1MMP2MMP3MMP7GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2173698-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF RENIN INHIBITORS SUCH AS ALISKIREN | Novartis Ag (CH) | 2010-04-14 | — | — | EP | disclosed |
| WO-2008155338-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | CYP1B1, CYP3A7, CYP2F1 | MMP1 2429/4885MMP2 2502/4885MMP3 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.